Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

50/433 Matches for
“biomarker standardization”

“biomarker standardization” Clear all
  1. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 100

    …Furthermore, NAFLD diagnosis relied exclusively on circulating biomarker-based liver scores, without…

    FibroTest NashTest SteatoTest Metabolic

  2. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 99

    …After standardization of estimates, analyses used curve fitting, quantitative Lin concordance coefficient…

    ActiTest FibroTest SteatoTest Alcohol +3

  3. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 98

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  4. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 97

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  5. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Match 96

    ### Background The area under the receiver operating characteristic (ROC) curve is widely…

    FibroTest HCV

  6. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

    Rosenthal-Allieri MA et al. · Gastroenterol Clin Biol · 2007 Match 95

    ### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…

    ActiTest FibroTest HCV

  7. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 94

    …As waiting for the perfect biomarker for the diagnosis of advanced fibrosis…

    ActiTest FibroTest SteatoTest Alcohol +5

  8. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 93

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  9. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 92

    …the “Control Population”, which enabled standardization of protein serum levels according to…

    FibroTest Metabolic

  10. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 91

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  11. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011 Match 90

    FibroTest HBV HCV HIV

  12. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 89

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  13. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 88

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  14. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 87

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  15. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 86

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  16. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 85

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  17. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 84

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  18. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 83

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  19. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 82

    FibroTest HCV

  20. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Match 81

    FibroTest HBV

  21. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 80

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  22. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 79

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  23. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Match 78

    ### Background The Fib-4 index is a simple and inexpensive biomarker to…

    FibroTest HBV

  24. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 77

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  25. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 76

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  26. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 75

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  27. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 74

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  28. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 73

    …for the evaluation of serum biomarker performance. The AUROCs of the Fibrotest…

    FibroTest HBV HIV

  29. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 72

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  30. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 72

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  31. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 70

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  32. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 69

    …Current non-invasive methods range from serum biomarker assays to advanced imaging…

    FibroTest Alcohol HBV HCV +3

  33. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 68

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  34. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 67

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  35. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 66

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  36. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 65

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  37. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 64

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  38. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 63

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  39. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 62

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  40. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 61

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  41. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 60

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  42. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 59

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  43. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 58

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  44. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 57

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  45. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 56

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  46. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 55

    FibroTest Alcohol HBV HCV +3

  47. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 54

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  48. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 53

    FibroTest Alcohol

  49. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 52

    FibroTest HBV

  50. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 51

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

Showing the full result list. The page is server-rendered and not paginated.